Introduction
Predominant features of rheumatoid arthritis (RA) are synovial hyperplasia, synovial cell activation, and articular inflammation associated with subsequent cartilage and bone destruction. 1 In this setting, T cell-independent pathways appear to be involved in numerous pathophysiologic pathways [1] [2] [3] [4] and one of the key players are transformed-appearing synovial fibroblasts, especially at sites of synovial invasion into adjacent cartilage and bone. 2, 4, 5 Molecular biology provides increasing evidence that upregulation of proto-oncogenes, intracellular signaling molecules, production of growth factors and cytokines, leads to metabolic activation of these cells followed by release of matrix degrading enzymes and progressive destruction of the affected joints. [4] [5] [6] [7] [8] [9] The involvement of cytokines, particularly of interleukin-1 (IL-1) and tumor necrosis factor ␣ (TNF-␣), in the pathogenesis of RA is well established, supported by results of numerous studies in animal models, [10] [11] [12] as well as in clinical trials. 13 Especially agents that inhibit secretion of these cytokines or that block their binding
and IL-1Ra double gene transfer resulted in inhibition of cartilage invasion and degradation by RA synovial fibroblasts when compared with control transduced and nontransduced implants. Expression of key genes that were altered after double gene transfer were related to the activin pathway. The results demonstrate not only that virus-based gene transfer using a combination of two joint-protective genes is a feasible approach to inhibit cartilage degradation by activated RA synovial fibroblasts, but also that the underlying molecular effects include modulation of the activin pathway.
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to cell surface receptors are potential therapeutics with increased specificity compared with common diseasemodifying antirheumatic drugs (DMARDs). These agents, which have been introduced into clinical medicine in the 1990s, include molecules such as cytokine-specific antibodies, 14, 15 soluble receptor molecules, 16, 17 and receptor antagonists. [18] [19] [20] Human IL-1 receptor antagonist (IL-1Ra) binds to both human IL-1 type I and type II receptors on cell surfaces, although with 100-fold greater avidity for IL-1 type I receptors. IL-1Ra competitively inhibits binding of both IL-1 alpha and IL-1 beta to cell surface receptors without inducing any discernible intracellular responses. A 100-fold or greater excess of IL-1Ra over IL-1 may be necessary to inhibit biological responses to IL-1 both in vitro and in vivo. All three forms of IL-1 may bind to IL-1 receptors in a similar fashion, but IL-1Ra may lack the secondary interactions necessary to trigger cell responses. 18 IL-1Ra is present physiologically in RA synovium, but not in sufficient amounts to inhibit the biological response to IL-1 in the inflamed joints. 18, 21 Several long-term clinical trials have been completed in which IL1Ra has been administered to patients with RA. 13, 19, 20, 22 The first trials with IL-1Ra in RA showed significant, but moderate, suppression of clinical disease activity. However, a beneficial effect on progression of joint erosion could be shown in a 6-month clinical trial. 20, [22] [23] [24] In addition to IL1Ra, other anti-inflammatory mechanisms responding physiologically to the proinflammatory pathways are operative in RA joints to control the dysregulated inflammatory activity. These pathways include the production of cytokines with anti-inflammatory properties, such as IL-4, IL-10 and IL-13, which are present in measurable, but not sufficient amounts in the RA joint. [25] [26] [27] A cytokine of particular interest as potential therapeutic agent for RA is IL-10. IL-10 is a 35 kDa homodimeric cytokine with both immunosuppressive and immunostimulatory properties depending on the target cell. The human and viral IL-10 (vIL-10, a product encoded by the Epstein-Barr virus) protein sequences are 84% identical with most of their divergence located in the 20 NH 2 -terminal amino acids. 28 vIL-10 shares many of the immunosuppressive properties of human IL-10 and murine IL-10, 28,29 but lacks their immunostimulatory properties including the T cell costimulatory activity. 30, 31 It also inhibits the production of proinflammatory cytokines, such as IL-1␤, IL-6, IL-8, TNF-␣, and granulocytemacrophage colony-stimulating factor produced by monocytes and synovial cells. In addition, IL-10 is able to decrease matrix metalloproteinases (MMP) production and to induce tissue inhibitor of metalloproteinases 1 (TIMP-1) expression by mononuclear cells. 32 As MMPs are involved in cartilage degradation, inhibition of these proteases by IL-10 supports the idea of a chondroprotective effect. IL-10 has also been studied in clinical trials for RA because of is down-regulatory effects on the production of proinflammatory cytokines by Th1 cells and monocytes. 26, 33, 34 To protect rheumatoid joints from destruction, especially at the sites of synovial invasion into the adjacent cartilage and bone, high amounts of protective molecules such as IL-1Ra and IL-10 are needed. Transfer of the respective genes into autologous cells in an ex vivo gene therapy approach has therefore been recently initialized and has currently been evaluated in a small series of RA patients. 35 However, as neither of the two molecules was able to suppress completely articular destruction in RA joints and the respective animal models, but showed ameliorating effects on different aspects of fibroblast-modulated cartilage destruction, 36, 37 the intention of the present study was to evaluate the effects of double gene transfer in the SCID-mouse model of cartilage erosion in RA. 5 In addition, to determine the molecular effects resulting from this double gene transfer approach, and to evaluate its impact on potential future clinical gene therapy trials, gene expression analysis using a combination of RAP-PCR and cDNA array was performed.
Results

vIL-10 and/or IL-1Ra expression after transduction and efficiency of gene transfer into RA fibroblasts
The control gene EGFP was expressed in up to 90% of the fibroblasts 48 h after transduction, depending on the MOI used for the experiments (data not shown).
Adenoviral transduction:
At the time of implantation of 4 IL-10 and 4 IL-1Ra transduced fibroblast populations into SCID mice (Figure 1 ), the concentration of vIL-10 protein in the supernatants were 628 ± 191 pg/ml (mean ± s.d.), and IL-1Ra protein 1184 ± 115 pg/ml. Double gene transfer resulted in the following protein concentrations (four SCID mice per group). DT: 511 ± 205 pg/ml vIL-10 and of 1117 ± 504 pg/ml IL-1Ra; ST: 362 ± 100 pg/ml IL10 and 637 ± 217 pg/ml IL1ra. No significant differences in protein production could be detected for separately performed transduction (ST) versus double transduction (DT) (Figure 2a ).
To confirm a constant cytokine expression during the 60 days after implantation into SCID mice, the vIL-10 and/or IL-1Ra expression was measured in serum of the SCID mice. In SCID mice with not transduced or control transduced fibroblasts, vIL-10 and IL-1Ra in serum was below the level of detection. Levels of transgene products reached 28 ± 14 pg/ml vIL-10 and 59 ± 24 pg/ml IL-1Ra in sera of the SCID mice inplanted with synovial fibroblasts. Following double gene transfer, protein levels of 65 ± 21 pg/ml for vIL-10 and 27 ± 5 pg/ml for IL-1Ra could be detected (Figure 2b ).
Retroviral transduction:
At the time of implantation of the four IL-10-or four IL-1Ra-transduced fibroblasts, vIL-10 protein concentration in the supernatants was 42 ± 14 pg/ml and 23 ± 10 pg/ml of IL-1Ra, respectively. No DT with detectable concentrations of both proteins could be performed. All double gene transfer experiments performed with retrovirally encoded vIL-10 and IL-1Ra in SCID mice were therefore performed by ST. Following implantation of retroviral transduced fibroblasts, the concentrations of vIL-10 or IL-1Ra in the sera of the SCID mice were below the detection level.
To exclude T or B cell activity of the SCID mice, serum ELISAs for mouse IL-6 were performed as a control. All SCID mice sera were negative for mouse and human IL-6 (data not shown).
Effects of vIL-10 and IL-1Ra overexpression on cartilage degradation in the SCID mouse model
The eight non-transduced and the eight EGFP controltransduced implants showed an intensive perichondrocytic cartilage degradation similar to previous experiments (Table 1) . 36, 37 At sites of invasion into the cartilage, numerous synovial fibroblasts could be detected ( Figure  3g -h). To confirm that the cells invading the cartilage were human RA synovial fibroblasts, immunohistochemistry using anti-human ␤2-microglobulin and antimouse/rat I-A antibodies was performed. Invading cells were positive for human ␤2-microglobulin, but not for anti-mouse/rat I-A (Figure 3g-h) .
The average degradation score of the eight non-transduced and the eight EGFP-transduced implants was 2.6 ± 0.3 (non-transduced) and 2.4 ± 0.4 (control transduced), respectively, illustrating that the vectors themselves or the overexpression of an irrelevant protein did not result in alterations of the behavior of the RA synovial fibroblasts (Figure 3a, b) . The grade of invasion also showed no significant difference between non-transduced (2.8 ± 0.2) versus control transduced (2.6 ± 0.6) implants.
Overexpression of vIL-10 (16 implants) resulted in a significant, nearly complete inhibition of cartilage invasion (0.3 ± 0.2), but did not affect perichondrocytic cartilage degradation (2.4 ± 0.2) (Figure 3c ). In contrast, overexpression of IL-1Ra (16 implants) resulted in a similar decrease of cartilage degradation (0.7 ± 0.6), but not of invasion (2.9 ± 0.2) (Figure 3d) , independent of the type of virus used for transduction and thereby adding to and confirming previous results. 36, 37 Most interestingly, in double gene transfer experiments of vIL-10 and IL-1Ra (24 implants) regardless of whether ST or DT was used, a highly protective effect towards invasion and degradation of the cartilage was observed Table 1 Scoring of SCID mice implants (invasion and degradation) as described in Materials and methods ( Figure 3e , f). This effect was also independent of the type of virus, as adenovirus DT (eight implants) showed an invasion score of 0.1 ± 0.2, adenovirus ST (eight implants) of 0.2 ± 0.2, and retrovirus ST (eight implants) of 0.2 ± 0.4. The degradation score of adenovirus DT was 0.1 ± 0.2, of adenovirus ST was 0.1 ± 0.2, and of retrovirus ST was 0.1 ± 0.2) All degradation and invasion scores are summarized in Table 1 .
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Differential gene expression of cytokines, oncogenes and tumor suppressor genes in RA synovial fibroblasts after overexpression of vIL-10 and IL-1Ra
cDNA arrays: RNA was isolated at day 4 and day 14 after transduction and was used for array experiments. Radioactive labeled cDNA probes were hybridized to cDNA array membranes. An example of the hybridizations is shown in Figure 4 demonstrating the cytokine expression pattern after transduction of vIL-10 and IL-1Ra of one patient in comparison to the expression pattern of nontransduced RA fibroblasts. Genes that were dysregulated after transduction with AdEGFP, ie that were dysregulated by the virus, were not regarded as relevant for the outcome of the experiment. For evaluation, results of cytokine stimulation (two RA patients) and supernatant transfer (two RA patients) were evaluated together with viral transduction (four RA patients). Supernatant transfer experiments were performed to exclude intracellular virus-mediated side-effects by the transduced cells. Stimulation experiments excluded effects of additionally produced cytokines by the transduced cells mediated by virus transduction. Both experimental settings were performed to guarantee vIL-10-and IL-1Ra-mediated molecular effects. Therefore, genes that were expressed differentially only following viral transduction or stimulation were not taken into account for the outcome of this study. In general, between eight and 14 genes (3-5%) were regulated differentially in one RA fibroblast population following double gene transfer depending on the RA patient (data not shown). Table 2 outlines the genes that were expressed differentially at day 14 after overexpression of vIL-10 or IL-1Ra and after vIL-10 and IL-1Ra gene transfer in all fibroblast populations and all experiments (Table 2, Figure 5 ).
Most strikingly, a small number of genes associated with the molecule activin were found to be altered in all double gene transfer experiments. Of these, activin A subunit, follistatin, and follistatin-related protein were Table 1. down-regulated, whereas inhibin was up-regulated. In addition, the tumor-suppressor genes p16INK4 and p33ING1, interleukins, interleukin precursors, and receptors involved in inflammation were differentially expressed after double gene transfer. IL-1␣ precursor, IL-4 precursor, IL-4 receptor ␣ subunit precursor and IL-10 receptor were up-regulated, whereas IL-5 receptor ␣ subunit precursor was down-regulated. In addition, the precursor of RANTES protein and CC chemokine receptor type 1 (RANTES) were down-regulated, and genes involved in matrix remodeling were up-regulated: BMPGene Therapy 2a, BMP-5, extracellular matrix metalloproteinase inducer (EMMPRIN).
(a) Non-transduced RA fibroblasts showed strong invasiveness into the cartilage together with perichondrocytic cartilage degradation (eight implants). (b) Adenovirus transduction of EGFP showed no effect on cartilage destruction (eight implants). (c) Adenovirus transduction with vIL-10 (eight implants) revealed decreased invasion when compared with nonand control-transduced implants. (d) IL-1Ra adenovirus-transduced fibroblasts (eight implants) showed decreased perichondrocytic cartilage degradation when compared with controls. (e) IL-1Ra and vIL-10 adenovirus transduced cells (16 implants) showed decreased invasiveness into the cartilage and reduced cartilage degradation. (f) IL-1Ra and vIL-10 retrovirus transduction (eight implants) resulted in cartilage protection, comparable to adenovirus double transduction. (g) Immunohistochemistry using mouse anti-human ␤2-microglobulin antibodies showing the human origin of the invading synovial fibroblasts. (h) Immunohistochemistry with mouse anti-mouse/rat I-A antibodies for staining of murine cells. Invasion and degradation scores are summarized in
The differential gene expression at day 4 after transduction corresponded with the gene expression pattern after day 14, except activin A subunit, p16INK4 and p33ING1, which showed a maximum expression at day 2 followed by a strong decrease of mRNA expression ( Figure 5 ). EMMPRIN was first down-regulated at day 3-4 after transduction and therafter up-regulated.
Confirmation of differentially expressed genes by realtime PCR
Differential gene expression was confirmed by real-time PCR for activin and follistatin. At first, activin could be found up-regulated after double gene transfer with vIL-10 and IL-1Ra, especially immediately after vector exposure. This effect led to measurable cytokine levels after 2 days of incubation. Thereafter, activin expression was down-regulated under the expression level before transduction, which was reflected in the pattern of cDNA expression experiments (Table 2) . Follistatin, its antagonist, was down-regulated after 2 days of protein expression. Figure 5 demonstrates a typical measurement using real-time PCR for activin at different time-points after transduction with RA synovial fibroblasts of one patient.
Confirmation of protein production by immunohistochemistry
Protein production in SCID mouse implants was performed by immunohistochemistry. Human activin and follistatin protein was evaluated in non-transduced, controltransduced and double-transduced fibroblasts. Nontransduced and control-transduced fibroblasts showed enhanced activin and follistatin protein production, and vIL-10-, as well as IL-1Ra-transduced fibroblasts showed reduced protein production in comparison to the controls ( Figure 6 ).
Discussion
IL-10 and IL-1Ra are of considerable interest as therapeutic agents for RA due to their anti-inflammatory and joint-protective properties. As neither of these molecules was able to inhibit articular destruction completely, the present study investigated the effects of vIL-1Ra and IL-10 double gene transfer in the SCID mouse model for RA.
Studies using cytokines and anti-cytokine therapies in animal models of arthritis and in patients with RA 13, 17, 19, 20, [38] [39] [40] have provided evidence suggesting a central role of these cytokines in the pathogenesis of RA. Among them, the first clinical trials using IL-1Ra in human RA demonstrated that IL-1Ra has a beneficial effect on the rate of progression of joint erosion, as well as on suppressing inflammatory disease activity. 19, 20 On the other hand, adequate clinical trials using IL-10 for RA treatment are lacking, but urgently needed, as physiological levels of IL-10, although produced in substantial amounts in the RA joint, appear insufficient to control inflammation. 26 However, as it could be shown recently that IL-1Ra and IL-10 are capable of inhibiting different aspects of cartilage destruction in the SCID-mouse model for RA, 36, 37 and as a recently performed clinical trial proved the feasibility of IL-1Ra ex vivo gene transfer in humans, 35, [41] [42] [43] [44] it appeared an intriguing question, as to whether double-gene transfer of IL-1Ra and IL-10 would reveal additive beneficial results on cartilage protection.
First, the present study shows that adenoviral vectors can be used to deliver simultaneously multiple genes with sufficient efficiency to control arthritis in the SCID mouse model for RA. The observation that stable serum levels of IL-1Ra and vIL-10 could be achieved for at least 60 days following gene transfer demonstrates that adenoviral vectors provide the desired long-term transgene expression for human trials, depending on the half-life and immunogenicity of the gene product. In addition, retrovirus transduction 35, 36 excluded adenovirusmediated side-effects.
Second, double gene transfer of IL-1Ra combined with vIL-10 resulted in nearly complete suppression of cartilage destruction when compared with IL-1Ra alone or vIL-10 alone. These differences were statistically significant in comparison to non-transduced and control-transduced fibroblasts. Histologically, an additive effect was observed between single gene transfer and double gene transfer in the protection of co-implanted cartilage (Figure 3 ).
Most interestingly, only 2-5% of the analyzed cytokines, oncogenes and tumor-suppressor genes were found to be differentially expressed in RA fibroblasts after blocking IL-1 and after overexpression of vIL-10 ( Table 2 ). Of these, distinct tumor suppressor genes that are involved in proliferation and growth inhibition were up-regulated after expressing IL-1Ra and vIL-10. Genes involved in the turnover of matrix, matrix degrading enzymes and their related proteins were down-regulated.
Third, and most strikingly, in all double gene transfer experiments, the effects of IL-1Ra and vIL-10 showed altered gene expression that could be associated with the activation and modulation of a pathway centered around the pleiotropic molecule activin and its functional antagonist follistatin. Activins belong to the transforming growth factor ␤ (TGF-␤) superfamily of dimeric proteins. They consist of ␤A and ␤B subunits which are connected by disulfide linkages. Three different forms of activins have been described, with similar activities of the three isoforms: the homodimeric activins A (␤A␤A), and B (␤B␤B), and the heterodimeric activin AB (␤A␤B). Recently, ␤C, ␤D and ␤E chains have been described. The activity of the activins are mediated by heteromeric Significant (P Ͻ 0.00043) after Bonferroni adjustment for oncogene and tumor suppressor gene arrays.
Figure 5 Real-time PCR for activin and follistatin. Real-time PCR to confirm cDNA array results was performed as described in methods. (a) Realtime PCR for activin. Example of one adenovirally transduced RA fibroblast population transduced with IL-10 and IL-1Ra at different time points. Day of transduction: d = 0. Experiments were performed in triplicates. (b) Real-time PCR for follistatin at day 4 after transduction. Example of one adenovirally transduced RA fibroblast population transduced with IL-10 and/or IL-1Ra or control transduced. Experiments were performed in triplicates.
Gene Therapy receptor complexes consisting of two different types of receptors, the type I (ARI and AR1b) and the type II receptors (ARII and ARIIb). In addition, a soluble activinbinding protein, follistatin, has been discovered which binds with high affinity to activin A and B and thereby inhibits its biological effects (for review see . Activins/inhibins are evolutionarily conserved, broadly distributed, 48 and influence many other processes, including inflammation, acute phase reaction, 49 proliferation and cell growth, 50 nerve cell survival and differentiation, 51, 52 tissue repair and wound healing, 53, 54 angiogenesis 55 and matrix and bone remodeling via BMPs (eg inhibition of osteoclastic cathepsin K-mediated bone reabsorption). [56] [57] [58] [59] [60] [61] A role of activin in the pathogenesis of inflammatory arthropathies has been suggested by Yu et al. 62 The latter demonstrated significantly elevated levels of activin A in the synovial fluid of patients with rheumatoid arthritis and gout, relative to those with osteoarthritis. The production of activin A by synoviocytes and chondrocytes in culture is up-regulated by cytokines such as IL-1, TGF-␤, interferon-␥, and IL-8. 62 Activin A has a potential to antagonize the local actions of IL-6 and IL-1. In contrast, IL-1 induces the action of activin A, and in vitro studies demonstrated a stimulatory effect of activin A on the expression of collagen type I mRNA in fibroblasts. 63 In our experiments, we could show that the pathways and effector molecules associated with activin are not only altered following IL-1Ra and vIL-10 double gene transfer, but that these specific alterations also provide the molecular basis for the understanding of the cartilage-protective effects of IL-1Ra and vIL-10.
In addition, the tumor suppressor genes p16INK4 and
Figure 6 Immunohistochemistry for human activin and follistation in SCID mouse implants. (a) Staining for human activin in an implant with nontransduced fibroblasts. (b) Staining for human activin in an implant containing vIL-10 and IL-1Ra overexpressing fibroblasts. (c) Staining for human follistatin in an implant containing non-transduced fibroblasts. (d) Staining for human follistatin in an implant containing vIL-10 and IL-1Ra overexpressing fibroblasts.
p21Cip1 50, 64 were found to be up-regulated after double gene transfer. Rheumatoid synovial fibroblasts express cyclin-dependent kinase (CDK) inhibitors, including p16INK4a and p21Cip1 when they are growth inhibited in vitro, 64 and p16INK4a gene therapy suppresses adjuvant arthritis of rats. 65, 66 This cartilage protective activity most likely adds to the effect of p21Cip1 in IL-4-and IL-10-mediated growth arrest and inhibition of proliferation ( Figure 7) . [67] [68] [69] [70] Besides p16INK4, the p33ING1 gene, a potential tumor suppressor gene which inhibits cellular growth in various tissues, 71 is up-regulated in RA synovial fibroblasts after double gene transfer.
Of interest, IL-4 precursor and IL-4 receptor ␣ subunit precursor were both up-regulated after double gene transfer. IL-4 together with IL-10 suppresses inflammation and joint destruction in RA. 72 IL-4 mediated growth arrest and IL-10 mediated inhibition of proliferation involve also p21CIP1, 73, 74 revealing additional effector mechanisms of vIL-10 and IL-1Ra double gene transfer (Figure 7) . Moreover, follistatin-related protein (FRP), which contains a similar amino acid sequences to follistatin, and is supposed to be an autoantigen in systemic rheumatic diseases, 75 was also down-regulated following double gene transfer of IL-1Ra and IL10.
Conversely, genes involved in matrix metalloproteinase activation and cartilage and bone remodeling were found to be down-regulated, especially the extracellular matrix metalloproteinase inducer (EMMPRIN), which enhances the synthesis of MMPs in fibroblasts and possesses tumorigeneic potential 76 (Table 2 ). These effects also explain in part the cartilage-protective effects of IL1Ra and vIL-10 observed in vivo.
In summary, the results of this study show that virusbased double gene transfer of joint-protective genes into rheumatoid synovial fibroblasts, known to be key players in destruction of cartilage and bone in rheumatoid arthritis patients, 3 is not only a feasible approach to inhibit both invasiveness as well as (perichondrocytic) cartilage degradation, but may be the basis for future clinical studies. 77 Moreover, IL-1Ra and vIL-10 double gene transfer revealed novel RA-associated pathways, ie the activin pathway, which in its complexity has hitherto not been associated with pathomechanisms leading to joint destruction in RA.
Materials and methods
Synovial tissue and cell culture
Synovial tissues were obtained from synovial biopsies of four patients with RA undergoing joint surgery (synovectomy or joint replacement by prosthesis implantation), who all met the criteria of the American College of Rheumatology. 78 Culture of synovial fibroblasts was performed as described recently. 5 Following enzymatic digestion, fibroblasts were grown in Dulbecco's MEM (Biochrom, Berlin, Germany) containing 10% heat inactivated fetal calf serum (Gibco Life Technologies, Grand Island, NY, USA), 100 U/ml penicillin and streptomycin (PAA Laboratories, Linz, Austria) and cultured for a maximum of four passages at 37°C in 10% CO 2 . Synovial fibroblasts were tested routinely for mycoplasms and stained for fibroblast markers by immunohistochemistry. 5 Mice Female Crl-scidBR mice, 4 weeks of age, were purchased from Charles River (Sulzfeld, Germany), and housed under Institutional Animal Care and Use Committeeapproved germ-free conditions.
Vectors and transduction
Adenoviral vectors: Each recombinant adenoviral vector originates from replication-deficient type 5 adenovirus lacking E1 and E3 loci. 79 cDNAs of the genes of interest were inserted in place of the E1 region, with expression driven by the cytomegalovirus promoter (CMV). AdEGFP encoded the enhanced green fluorescent protein, AdvIL-10 the viral IL-10 protein, and AdIL-1Ra the human IL-1 receptor antagonist, all under control of the CMV promoter. All experiments were performed in duplicates with RA synovial fibroblasts of each of the four patients transduced separately or double transduction of fibroblasts with both, vIL-10 and IL-1Ra.
Adenoviral transduction:
For adenoviral transduction in vitro, 5 × 10 5 fibroblasts per well were grown in six-well plates as described above. The cells were washed with saline solution, and 10-30 MOI (multiplicity of infection) of adenovirus in a volume of 500 l saline were added. For double gene transfer, both viruses with equal MOI were added in 500 l saline. After incubation at 37°C for 2 h, virus containing medium was replaced by 2 ml DMEM. Forty-eight hours after transduction, culture supernatant was removed and 500 l were stored for cytokine measurements at Ϫ20°C. 1.5 ml supernatant were used for further experiments. After 48 h, culture supernatant was removed and IL-1Ra/vIL-10 protein production was confirmed by ELISA. After confirmation of transgene expression, half of the cells separately transduced with vIL-10 and IL-1Ra transduced cells were mixed (separate transduction, ST). Cells transduced with vIL-10 and IL-1Ra in one well (double transduction, DT) were cultured in parallel until implantation into SCID mice or RNA isolation.
Retroviral vectors:
The construction of a ⌿-CRIP producer line for MFG-constructs, such as MFG-IRAP, has been described recently. [80] [81] [82] Retroviral transduction: For retroviral transduction in vitro, 5 × 10 5 fibroblasts per well were grown in six-well plates as described above. Cells were washed with saline solution, and 50-200 MOI of retrovirus were added in a volume of 300 l DMEM containing 8 g/ml polybrene. Transduced cells were incubated for 8 h, followed by cenGene Therapy trifugation for 2 h (3000 r.p.m. at 4°C or room temperature). Virus containing supernatants were changed and cells incubated for an additional 8 h, then the virus containing medium was replaced by 2 ml DMEM. After 48 h, culture supernatants were removed and the production of IL-1Ra/vIL-10 proteins confirmed by ELISA. When necessary due to low protein production, cells were retransduced after 48 h to increase transduction efficiency. Supernatants were removed and 1.5 ml of supernatants were used for further experiments.
The following cells were used for the SCID mouse experiments and the implants (two implants per mouse): four RA fibroblast populations, non-transduced (eight implants); four control-transduced fibroblast populations (eight implants); four adenoviral and four retroviral IL-10-transduced fibroblast populations (eight implants each); four adenoviral and four retroviral IL-1Ra-transduced fibroblast populations (eight implants each); four adenoviral seperately (ST), four double (DT) and four retroviral (ST) transduced fibroblast populations (eight implants each).
Stimulation with recombinant IL-1Ra and vIL-10
To evaluate potential virus-mediated intracellular sideeffects, 5 × 10 5 non-transduced synovial fibroblasts per well of two patients (which were used also for transduction experiments) were stimulated with IL-1Ra and vIL-10 in six-well plates.
Stimulation: After washing, cells were stimulated with 2 ml DMEM containing similar amounts of vIL-10 or IL1Ra protein as those achieved by retro-or adenoviral transduction. Cells were cultured in parallel to the transduced cells.
Supernatant transfer experiments
To evaluate potential effects caused by viral transduction (ie by the virus itself), 5 × 10 5 non-transduced RA synovial fibroblasts per well of two patients which were also used in transduction experiments were washed, and the cell culture supernatants were replaced with supernatant of the transduced cells (total volume 1.5 ml) and 500 l fresh DMEM.
Cytokine assays
Concentrations of vIL-10 or IL-1Ra in the cell culture supernatants or in the blood of all SCID mice were evaluated by ELISA, measuring serial dilutions of untreated cells or cells transduced with adenoviruses containing the vIL-10, IL-1Ra or the EGFP gene. Before ELISA, all cell culture supernatants were stored at Ϫ20°C. ELISA kits for human IL-1Ra, IL-10, follistatin, activin, human, and mouse IL-6 were purchased from R&D (Wiesbaden-Nordenstadt, Germany). Measurements were performed according to the manufacturer's protocol.
RNA extraction
At 80% confluency, cultured fibroblasts were harvested and total cellular RNA was extracted using the RNeasy spin column purification kit (Qiagen, Hilden, Germany) in combination with the RNase-free DNase Set (Qiagen). RNA concentrations were measured using the Ribogreen RNA quantification kit (Molecular Probes, Leiden, The Netherlands), and stored at Ϫ70°C.
RNA arbitrarily primed PCR (RAP-PCR) of total cellular
RNA RAP-PCR of total cellular RNA was performed as described previously. 83, 84 First-strand synthesis was carried out using MuLV reverse transcriptase (Promega, Madison, WI, USA), 250 ng of RNA and 2 M first-strand arbitrary primer. Second strand synthesis was performed for 35 low stringency cycles (30 s 94°C, 30 s 35°C, 30 s 72°C) using AmpliTaq Stoffel Fragment (Perkin Elmer, Norwalk, CT, USA) and 4 M second arbitrary primer.
Twelve different primer combinations were tested. The following arbitrary primers yielded the best results: OPN23 (5Ј-CAG GGG CAC C-3Ј) for first-strand and OPN21 (5Ј-ACC AGG GGC A-3Ј) for second-strand synthesis, and as second combination for cytokine arrays OPN21 for first-strand synthesis and US6 (5'-GTG GTG ACA G-3') for second strand synthesis. 2 l of PCR reactions were separated on an 8 M urea/6% polyacrylamide gel and electrophoresed. After confirmation that the RAP-PCR was successful, the PCR products were hybridized on Atlas cDNA Expression Array (Clontech, Palo Alto, CA, USA) membranes.
RAP-PCR and Atlas cDNA expression array
Two Atlas human cDNA expression array membranes (Clontech) containing the cDNAs from 190 known oncogenes and tumor suppressor genes or 200 cytokines and nine housekeeping genes were used.
Preparation of cDNA probes: cDNA was amplified in a 20 l reaction by RAP-PCR as described above using 2.8 l ␣-32 P-dATP (3000 Ci/mmol, 10 mCi/ml) in the second-strand synthesis. PCR reaction was purified from unincorporated 32 P-labeled nucleotides and small cDNA fragments (Ͻ0.1 kb) by column chromatography using NucleoSpin Extraction Kit (Clontech) as outlined by the producer. A total volume of 100 l was used for hybridization. 2 l of the purified probe was measured by scintillation counting.
Hybridization: Hybridization was performed in roller bottles. The Atlas human cDNA expression array membranes were prehybridized in 5 ml prewarmed (68°C) hybridization solution (ExpressHyb Hybridization Solution, Clontech) with 100 g/ml fragmented denatured salmon sperm DNA in a hybridization oven. The labeled cDNA probe was diluted 1:10 with 10× denaturing solution (1 M NaOH, 10 mM EDTA) and incubated at 68°C for 20 min. 5 l (1 g/l) sheared human genomic DNA and an equal volume of 2× neutralizing solution (1 M NaH 2 PO 4 , pH 7.0) was added and incubated for 10 min at 68°C. The mixture was added to the filters and the hybridization solution, and hybridized overnight.
Wash: The filters were washed three times in 2× SSC and 2% SDS for 15 min at 68°C. One washing step was performed with 0.1× SSC and 0.5% SDS at 68°C for 15 min and one step for 5 min at room temperature in 2× SSC. Then the filters were exposed to a Phosphor-Imager-Screen (Molecular Dynamics, Sunnyvale, CA, USA) for about 3 days depending on the intensity of radiation of the bound fragments. Data analysis was performed using the Ambis software (ImageQuant, Molecular Dynamics).
Evaluation of cDNA arrays: Evaluation was performed using the AtlasImage 2.0 software, developed specifically for analysis of the Atlas cDNA Expression Arrays (Clontech). Arrays were adjusted and aligned to the Array Image View as described by the manufacturer. In general, about 104 ± 11 genes out of 190 spotted oncogenes and tumor suppressor genes and 95 ± 6 out of 200 cytokines on the array membranes could be analyzed.
Statistics: Statistical evaluation was performed using Lavene-statistics followed by t test. For multiple comparisons, statistical significance levels were adjusted respective to the number of compared genes (Bonferroni adjustment). For each cytokine array, 95 ± 6 cDNAs could be compared using the primer combination as described above, therefore P = 0.05 was divided by 101, and P values lower than 0.00049 were regarded as significant.
For each oncogene and tumor suppressor gene array, 104 ± 11 cDNAs could be compared using the primer combination as described above. Applying the Bonferoni adjustment, P values lower than 0.00043 were regarded as significant.
'Inverse Wrap' technique for tissue implantation into the SCID mouse
Preparation of fibroblasts and cartilage: Synovial fibroblasts were cultured and transduced. Immediately before implantation, fibroblasts were trypsinized, spun down and resuspended in saline solution in a final volume of about 100 l for each sponge. The implantation procedure was performed as published recently. 85 In brief, the cartilage was cut into 1-5 mm 3 pieces. One piece was immediately snap frozen and stored at Ϫ70°C and served as control for scoring after explantation. A niche was scratched into a sterile sponge and the cartilage inserted. The sponge with the cartilage was soaked with the resuspended fibroblasts.
Implantation: Implantation of the sponge under the skin was performed under sterile conditions. Two implants containing aliquots from the same population of fibroblasts were inserted under the skin at the left flank of the SCID mouse (Figure 1 ). In brief, 4-week-old SCID mice were examined for macroscopic anomalies, as well as for macro-and histopathologic abnormalities after death. At the day of implantation, normal human cartilage was obtained from non-arthritic knee joints of patients undergoing routine surgery at the Department of Orthopedics at the University of Regensburg. A cube of inert sponge (Ϸ80 mm 3 ) was incised and a piece of cartilage (5-8 mm 3 ) was inserted. The sponge was soaked with 5 × 10 5 fibroblasts suspended in sterile saline. The skin of the anesthetized mouse was opened surgically and up to three pieces of sponge containing cartilage and fibroblasts were inserted. After 60 days, the mice were killed, the implants were removed and embedded immediately in TissueTek embedding medium (Miles, Elkhart, IN, USA), snap-frozen and stored at Ϫ70°C until further use. At the day of explantation, mouse serum was collected and tested for protein production by ELISA.
Histological evaluation of implants
Immediately after explantation, explants (including a sample of murine skin) were snap frozen in liquid nitrogen and stored at Ϫ70°C. 500 l murine blood was taken to analyze the serum concentrations of vIL-10 and IL-1Ra.
Using standard hematoxylin-eosin staining, each specimen was evaluated for the grade of invasion of fibroblasts into cartilage and perichondrocytic cartilage destruction as published recently. 36, 37 Invasion scores: 0, no or minimal invasion; 1, visible invasion (two cell depths); 2, invasion (five cell depths); 3, deep invasion (>10 cell depths).
Perichondrocytic cartilage degradation scores: 0, no degradation (sharp, intact halo of the chondrons compared with the cartilage stored before implantation into the SCID mice); 1, visible degradation (one diameter of the chondron); 2, degradation (between one and two diameters of the chondron); 3, intensive degradation (> two diameters of the chondron). Statistical analysis was performed using the t test for nonparametric data, and P values Ͻ0.05 were regarded as significant. Each scoring was performed by three different researchers for all patients. Scores were evaluated for all implants.
Immunohistochemistry
This method was used for the detection of human cells (ie synovial fibroblasts) and human activin or human follistatin in the SCID mouse implants. Snap frozen sections of the SCID mouse implants (4-6 m) were cut, fixed and blocked with a 4% milk, 2% normal horse serum Tris buffer for 30 min. Then, slides were washed in Tris buffer and incubated for 45 min with mouse anti human ␤2-microglobulin (Serotec, Oxford, UK); mouse anti mouse/rat I-A (Serotec); mouse anti human activin A (R&D, Wiesbaden, Germany), or mouse anti-human follistatin (R&D). Slides were rinsed in Tris buffer and incubated for 30 min with a secondary biotinylated goat antimouse antibody (Jackson, West Grove, PA, USA) diluted 1:600 in Tris buffer. Incubation with the AEC substrate (Vector Laboratories, Burlingame, CA, USA) was performed for 30 min at room temperature. The color development (varying from 10-30 min) was stopped under microscopic examination by washing with water. After staining with hematoxylin, the slides were immediately mounted (Gel Mount; Biomeda, Foster City, CA, USA).
Real-time PCR
Real-time PCR was performed using a LightCycler system (Roche Diagnostics, Mannheim, Germany) according to the manufacturer's instructions. Reactions were performed in a 20 l volume with 0.5 M primers (Activin-f: 5'-AAAAGAAGGGCGGAGGTGAA-3'; Activin-r: 5'-TGG AAGGACAGTGAGGACCC-3'; Follistatin-f: 5'-AAACG TGTGAGAACGTGGAC-3'; Follistatin-r: 5'-TCCGATTA CAGGTCACACAG-3'; 18S-for 5'-TCAAGAACGAAA GTCGGAG-3'; 18S-rev: 5'-GGACATCTAAGGGCAT-CACA-3'), 3 mM (18S, activin) or 4 mM (follistatin) MgCl 2 concentration, and 2 l LightCycler-FastStart Reaction Mix SYBR Green I (Roche Diagnostics). After 10 min polymerase activation at 95°C, 40 cycles with 95°C for 15 s, 59°C (activin)/50°C (follistatin) for 5 s, 72°C for 20 s were performed. Fluorescence was measured at the end of the 72°C extension period. Efficiencies of the primers were tested using the standard curve method (E = 10
Ϫ1/slope
). According to the guidelines of the manufacturer, efficiencies of 2.00 ± 0.05 were considered acceptable for experiments. Efficiencies of primer pairs for relative quantification were identical or nearly so. To confirm Gene Therapy amplification specificity, the PCR products from each primer pair were subjected to a melting curve analysis to exclude primer dimers and non-specific amplification. Data were analyzed using the LightCycler analysis software (Roche) as outlined by the manufacturer. The baseline of each reaction was equalized by calculating the mean value of the five lowest measured data points for each sample and subtracting these values from each reading point. Background fluorescence was removed by setting a noise band. In this setting, the number of cycles at which the best-fit line through the log-linear portion of each amplification curve intersects the noise band is inversely proportional to the log of copy numbers. 86, 87 The crossing points (CP) are the intersections between the best fit lines of the log-linear region and the noise band. The CP determined for follistatin and activin were normalized to those of 18S RNA to compensate for variabilities in the amount of RNA and for exclusion of general transcriptional effects.
